High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes (PRIME)
High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes; PRIME: P: Precision R: Radiosurgery I: Intervention M: Minimal Invasive Surgical Approach E: EYESIGHT
High-precision radiosurgery followed by minimally invasive surgical approach in patients with high-prominence uveal melanomas: modern radiation techniques and outcomes. Evaluation of outcome regarding multiparametric parameters and co-factors
研究概览
详细说明
The aim here is to prospectively evaluate modern technical standards. The aim of this study is to assess the influence of the updated basic diagnostics and high-resolution diagnostics for radiation planning and the new technical therapy standards (therapy options in application: volume modulated rapid arc technique (VMAT) / online arc technique (VMAT) / online onboard image-guidance (IGRT), by means of the newly established Clinic for Radiation Therapy 2019-2021) depending on known prognostic parameters for quality assurance of the long-term outcome (overall survival, local tumor control). This will lay the basis for standardizing treatment parameters as far as possible, but also to introduce improvements in the treatment of future patients.
Scientific background (state of research (with literature references) and
Derivation of the research question (rationale)):
The eye can be affected by several neoplastic processes, which can lead either primarily or secondary to systemic metastasis. The most common primary tumors of the eye include conjunctival melanoma and uveal melanoma. Metastases from systemic malignant diseases, particularly of the breast and lungs, can also affect the eye.
A combination of ophthalmologic examination, MRI and additional tests and cytologic/histopathologic evaluation leads to an accurate diagnosis.
Depending on the tumor manifestation, treatment consists of a multimodal concept. In the case of uveal melanomas and the aim of preserving the globe and and visual acuity preservation, radiotherapy is one of the most important treatment modalities that can be applied.
In the last 20 years, radiotherapy has developed rapidly away from two-dimensional modulated, three-dimensional techniques. But here too the high level of technical diversity in radiotherapy and ever newer technical innovations, there is a broad spectrum of radiotherapy. Standard therapy can be performed using modern devices, the high-precision stereotactic linear accelerators (irradiation devices), can be safely further optimized. This is to be tested in the Department of Radiotherapy.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Maja Guberina, PD MD
- 电话号码:0201 723 83121
- 邮箱:maja.guberina@uk-essen.de
学习地点
-
-
-
Essen、德国
- 招聘中
- University Hospital Essen
-
接触:
- Maja Guberina
- 电话号码:+4920127232321
- 邮箱:maja.guberina@uk-essen.de
-
Essen、德国、45147
- 招聘中
- Maja Guberina
-
接触:
- Maja W Strahlentherapie
- 电话号码:+492017232321
- 邮箱:maja.guberina@uk-essen.de
-
-
Germany / NRW
-
Essen、Germany / NRW、德国、45147
- 招聘中
- Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
-
接触:
- Maja Guberina, PD Dr. med. (MD), specialist
- 电话号码:+492017232321
- 邮箱:maja.guberina@uk-essen.de
-
接触:
- Ina Grübel
-
首席研究员:
- Maja Guberina, PD Dr. med. (MD)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Inclusion Criteria:
- Resectability, high-prominent and high risk uveal melanoma
Exclusion Criteria:
- EOE
- lux defect (If a medical report notes a "lux defect" alongside this, it refers to a deficit in light perception (from the Latin lux for light). It means the eye's ability to sense light, darkness, or light direction is impaired)
描述
Inclusion Criteria:
- Functional Resectability,
- Technical Resectability
- high-prominent uveal melanoma
Exclusion Criteria:
- EOE
- At least in part remaining eye function that can be saved
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Local control
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Local control |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual acuity:
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Quality of Life, ophthalmic cancer-specific quality of life
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Quality of Life, ophthalmic cancer-specific quality of life 1) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties. |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Progression Free Survival
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Progression Free Survival |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Overall Survival
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Overall Survival |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual acuity:
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual field
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%, |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Quality of Life general quality of life
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales. |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Retinal Nerve Fiber Layer
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values) |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Cornea
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
corneal outcome: thickness measured in µm |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Cornea
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Corneal outcome modified Stocker's classification: category 0 No damage no injury category 1 corneal guttae without epithelial or stromal edema. category 2 corneal guttae with epithelial or stromal edema. category 3 corneal edema associated with scar formation. category 4 corneal opacification with neovascularization, modified Stocker's classification |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Corneal overall outcome classification
大体时间:At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
category 0 No corneal-ulcus category 1 Irregular punctate epithelial defects category 2 Non-healing epithelial defects / persistent epithelial defect (PED) category 3 Ulcer perforation |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 21-10377-BO
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
dependent on the project
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.